News Highlights

November 9, 2009
Concert Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor for Treatment of HIV; Concert Earns $12 Million Milestone from GlaxoSmithKline

November 3, 2009
Concert Pharmaceuticals to Participate on a Private Company Panel at the Merriman Curhan Ford 6th Annual Investor Summit

October 29, 2009
Concert Pharmaceuticals’ Roger Tung Awarded 2009
Mass High Tech All Star Award

October 13, 2009
Concert Pharmaceuticals Selected by AlwaysOn as an OnDC Top 100 Winner; Recognized for Innovative Technology for Game-Changing New Medicines

more...

Welcome to Concert

Concert uses deuterium-based chemistry to create and develop highly differentiated new medicines, leveraging proven drugs to reduce risk. This approach results in:

• Reduced risk;
• Rapid R&D; and
• New intellectual property.

Upcoming Events

Concert will present at the 28th Annual J.P. Morgan Healthcare Conference taking place January 11-14, 2010 in San Francisco.

Concert in the news... a selection of news stories featuring Concert.